SCARLETRED Holding GmbH
- Funded by Austrian Research Promotion Agency (FFG)
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Funder
Austrian Research Promotion Agency (FFG)Principal Investigator
N/A
Research Location
AustriaLead Research Institution
SCARLETRED Holding GmbHResearch Priority Alignment
N/A
Research Category
Clinical characterisation and management
Research Subcategory
Supportive care, processes of care and management
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Unspecified
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable
Abstract
KLIPHA-COVID19: Use of recombinant human superoxide dismutase (rhSOD) in the treatment of severe pneumonia and SARS in COVID-19 patients. DE SCARLETRED's rhSOD (recombinant human superoxide dismutase) treatment of COVID-19 pneumonia offers a first therapeutic approach which directly targets the inflammatory cascade in the lungs and other organs by increasing the elimination of radical oxygen species (ROS). This is intended to counteract further damage caused by COVID-19 in the lungs and other organs.